Raisa S. Kosharnaia

Raisa S. Kosharnaia

Auto-generated profile, based on publicly available information

Raisa S. Kosharnaia

Endocrinology Research Centre

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2024 in Cardiac Failure Review
Verified
Journal Article
Open access
PDF file
ABAleksandra A. Bykova
Aleksandra A. Bykova
MSMaria Serova
Maria Serova
MCMaria Chashkina
Maria Chashkina
RKRaisa Kosharnaya
Raisa Kosharnaya
ZSZukhra Salpagarova
Zukhra Salpagarova
IGIlya Giverts
Ilya Giverts
This review examines the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on different heart failure phenotypes with preserved ejection fraction (HFpEF). Traditional heart failure treatment modalities have shown limited success in improving outcomes for patients with HFpEF, but new evidence suggests that GLP-1RAs could be beneficial. The positive effects of GLP-1RAs are likely due to their ability to reduce systemic inflammation, enhance metabolism and directly affect the cardiovascular system, addressing critical aspects of HFpEF pathology. However, the exact impact of GLP-1RAs on clinical outcomes for different HFpEF phenotypes is still unclear. This review highlights both the potential benefits and the current limitations of GLP-1RA therapy, suggesting a careful approach for their application in clinical practice.

16 January 2023 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
RKRaisa S. Kosharnaia
Raisa S. Kosharnaia
ZBZhanna Belaya
Zhanna Belaya
ZZZamira T. Zuraeva
Zamira T. Zuraeva
MMMarina S. Michurova
Marina S. Michurova
VKVictor Y. Kalashnikov
Victor Y. Kalashnikov
Aim. To evaluate frequency of heart failure syndrome in patients with endogenous hypercortisolism and to establish relationship between effective treatment for hypercortisolism and regression of heart failure with particular emphasis on the observation of NT-proBNP and ST2 levels. Materials and methods. 56 patients with endogenous hypercortisolism (45 female, mean age 47 years [36; 55] hospitalized with endogenous hypercortisolism to National Medical Research Center for Endocrinology were enrolled in the study. All patients underwent comprehensive clinical investigation including expert echocardiography with speckle tracking and evaluation of NT-proBNP and ST2 cardiac biomarkers at baseline and 6 months after surgical treatment. Results. According to clinical data and elevated biomarkers of cardiac stress 28 out of 56 patients (50%) at baseline met the criteria for heart failure. 20 patients were included in the final analysis. Follow-up investigation with focus on changes in NT-proBNP and ST2 levels demonstrated that surgical correction of endogenous hypercortisolism resulted in resolution of heart failure syndrome in 11 patients (55%). Conclusion. These preliminary data suggest that signs and symptoms of heart failure are observed in patients with endogenous hypercortisolism in about half the cases. Surgical correction results in resolution of heart failure in approximately two thirds of the cases. Prospective evaluation NT-proBNP and ST2 levels may provide important diagnostic and prognostic information in patients with endogenous hypercortisolism.

9 December 2024 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
AAAlina A. Almaskhanova
Alina A. Almaskhanova
KMKonstantin V. Melkozerov
Konstantin V. Melkozerov
EPElena Przhiyalkovskaya
Elena Przhiyalkovskaya
NTNatalia V. Tarbaeva
Natalia V. Tarbaeva
AKAnastasya Y. Korneluk
Anastasya Y. Korneluk
КЮКорнелюк Анастасия Юрьевна
Корнелюк Анастасия Юрьевна
Aim. To determine the incidence of interstitial myocardial fibrosis (MF) in acromegaly, which leads to the development of cardiac arrhythmias and conduction disorders. Materials and methods. A single-center study was conducted, including 70 patients with acromegaly. All patients underwent standard medical examinations, including hormonal blood tests, electrocardiograms, echocardiography, Holter monitoring electrocardiograms and magnetic resonance imaging (MRI) of the heart with gadolinium contrast, additionally 48 patients underwent T1-mapping, which is an MRI method that allows the detection of diffuse changes by measuring the values of myocardial relaxation time – T1. Results. The study revealed a high incidence of MF – 53 (75.7%) cases (21 women, 32 men). The duration of the disease was found to be critical for myocardial remodeling (p=0.006). Compliance criteria for the T1-mapping technique were determined, with reduced T1-mapping values observed in 85.2% of cases. The ROC analysis (Receiver Operator Characteristic) determined the diagnostic value of post-contrast T1-mapping: AUC (Area Under the Curve)=0.906 (95% confidence interval 0.789–1.000), a sensitivity of 90%, and a specificity of 76.5%, indicating high diagnostic efficiency. According to the Youden index, a cut-off point of 372.5 ms was selected. Conclusion. Myocardial T1-mapping is a novel MRI method that allows to assess the degree of MF without the need for myocardial biopsy. The obtained information is crucial for the diagnosis and prognostic assessment of heart diseases, particularly in cases of hypertrophic cardiomyopathy or infiltrative diseases. The T1-mapping method, which is actively developing, can serve as a marker for early diffuse myocardial fibrosis and help determine the prognosis for patients with acromegalic cardiomyopathy.

30 November 2022 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
AVAnastasia Voznesenskaya
Anastasia Voznesenskaya
IBI. Z. Bondarenko
I. Z. Bondarenko
KMK. V. Melkozerov
K. V. Melkozerov
RKR. S. Kosharnaya
R. S. Kosharnaya
AZA. S. Zakharov
A. S. Zakharov
VKV. Yu. Kalashnikov
V. Yu. Kalashnikov
Diabetes mellitus (DM) type 1 accounts for up to 90% of all cases of diabetes among children, adolescents and young adults (10 % are represented by T2DM, MODY, etc.). DM is characterized not only by glucose metabolism disorder, but also by abnormal protein and lipid metabolism, leading to severe macrovascular complications. A clinical case of diabetes type 1, hyperlipidemia, coronary artery disease (CAD) and chronic heart failure (HF) in a 25-year-old adult has been demonstrated. The medical examination revealed lipid metabolism disorders, multivessel coronary artery disease, which required myocardial revascularization, and severe heart failure with a reduced ejection fraction (HFrEF). The clinical case demonstrates that proper cardiovascular examination should be performed in all patients with diabetes and lipid disorders, regardless of age and type of diabetes. The authors also consider the use of sodium-glucose

7 October 2021 in Siberian Journal of Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
OVO. I. Vengrzhinovskaya
O. I. Vengrzhinovskaya
IBI. Z. Bondarenko
I. Z. Bondarenko
OSO. A. Shatskaya
O. A. Shatskaya
RKR. S. Kosharnaya
R. S. Kosharnaya
MSMarina Shestakova
Marina Shestakova
Type 1 diabetes mellitus (T1DM) triggers disruption of oxygen transport system in patients. The maximum oxygen consumption (VO2 max) during spiroergometry depends on the functional capabilities and composition of the body. Moreover, VO2 max may be considered a predictor of pathological changes in cardiovascular system.Aim. The purpose of the study was to investigate the compositional body characteristics and functional cardiorespiratory parameters in T1DM patients.Material and Methods. The study comprised 30 patients with T1DM (average age of 25.5 ± 8.1 years) and 10 patients of control group (average age of 27 ± 9 years). Patients received spiroergometry examination according to B. Bruce protocol and bioimpedansometry using the Inbody 770 apparatus. The study showed that T1DM patients reached anaerobic threshold faster (p = 0.032) and had significantly lower VO2 max and carbon dioxide emission compared to patients without diabetes (p = 0.021; p = 0.034) whereas exercise tolerance did not significantly differ compared with the corresponding value in control group. Patients with higher muscle mass i.e. muscle tissue weight (kg) according to bioimpedance measurements had higher values of VO2 max (L) in control group (p = 0.017) and in group of T1DM patients (p = 0.028).Conclusions: Young T1DM patients without cardiovascular diseases had significantly less effective cardiorespiratory system compared with that in people without diabetes even in those with high exercise tolerance. Rapid achievement of anaerobic threshold with preserved performance efficiency was a sign of unfavorable prognosis. Body mass index and lean body mass did not significantly affect the performance parameters in young T1DM patients. Screening of spiroergometry parameters may be used for identification of young T1DM patients at high risk of unfavorable cardiovascular diseases including chronic heart failure.

19 June 2024 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
AAA. A. Almaskhanova
A. A. Almaskhanova
KMK. V. Melkozerov
K. V. Melkozerov
EPElena Przhiyalkovskaya
Elena Przhiyalkovskaya
NTN. V. Tarbaeva
N. V. Tarbaeva
RKR. S. Kosharnaia
R. S. Kosharnaia
NMN. G. Mokrysheva
N. G. Mokrysheva
The most common causes of death in acromegaly are cardiovascular diseases (about 60%). Heart arrhythmias and conduction disorders lead to sudden cardiac death (SCD). In this article, we described a clinical case about preventing SCD in a patient with acromegaly. We identified in this patient predictors of SCD: severe left ventricular hypertrophy, the signs of myocardial fibrosis, decreased systolic function of the left ventricular myocardium, ventricular rhythm disturbances, and heart failure. Patients with acromegaly have higher risk of heart arrhythmias due to development acromegalic cardiomyopathy with includes: left ventricular hypertrophy, diastolic and systolic dysfunction, myocardial fibrosis and electrical disturbances of the myocardium. The main limitation is the lack of special clinical recommendations for the management of this group of patients. Current recommendations based on a standard algorithm and do not consider specificity of acromegalic cardiomyopathy.